Trial Profile
Cross-sectional study reporting the development of drug resistance mutations unique to etravirine and rilpilvirine exposure occurring in Kenyan HIV patients on HAART
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2015
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Nevirapine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 20 Dec 2015 New trial record